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Following rapid expansion of anti-retroviral therapy (ART) in resource limited settings, 
some patients are failing and require switching to second line ART. The diagnosis of treatment 
failure in these settings depends on relatively poorly performing WHO immunological failure 
criteria. As a consequence, physicians are reluctant to switch patients to second-line and hence, 
times to switch to second line varies substantially in different programs. Despite the efforts to 
address the importance of ART adherence, some patients receiving second-line ART are still 
non-adherent. Limited treatment options underscore the need to explore adherence as well as 
switching times among patients receiving second-line. 
A review of 637 adolescents and adults meeting WHO immunological failure criteria was 
conducted. Immediate and delayed switching to second-line ART were defined when switching 
happens at < 3 and ≥ 3 months respectively following failure diagnosis. Those receiving second-
line were administered questionnaires that assessed adherence. Optimal and suboptimal 
cumulative adherence were defined as percentage adherence of ≥ 90% and < 90% 
respectively.  Cox proportional hazard marginal structural models were used to assess the 
effect of switching to second-line ART and the risk of opportunistic infections and binomial 
regression models were used to assess the prevalence of suboptimal adherence percentage by 
pre-switch adherence status. Among 322 participants who had suboptimal adherence to first-
line ART, 117 (36.3%) had suboptimal adherence to second-line ART compared to 17/114 
(14.9%) who had optimal adherence to first-line. Of 637 participants 74% (n=471) were either 




ART were more likely to have suboptimal adherence to second-line ART (APR 2.4, 95% CI 1.5 
– 3.9).Switching to second-line ART reduced the risk of opportunistic infections (adjusted 
hazards ratio [AHR] 0.4, 95% CI 0.2 – 0.6). Compared to patients who switched to second-line 
ART immediately after failure diagnosis is made, those who delayed switching exhibited a trend 
toward more opportunistic infections (AHR 1.7, 95% CI 0.6 – 4.4). 
Interventions to improve adherence to patients with suboptimal adherence prior to switch 
as well as increasing physician’s awareness about when to switch to second-line ART is critical 
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CHAPTER 1: SPECIFIC AIMS 
As the access to anti-retroviral therapy (ART) expands in resource limited settings, 
substantial proportions of patients are failing and hence require switch to second-line therapy.1-4 
Due to the laboratory infrastructure and costs associated with routine viral load monitoring, 
switching to second-line in resource limited settings is entirely dependent on clinical grounds 
and immunological failure criteria. In this context, virological relapse may not be recognized and 
the identification of treatment failure may be delayed until participants have a decline in CD4+ 
cells or clinical manifestations of progressive disease. Despite high potency of second-line ART 
in viral suppression and restoration of immunity, its success requires optimal adherence to 
medication.5-8 
Suboptimal adherence continues to be the main concern among patients receiving 
second line ART. Given that second line ART is the last treatment option in many parts of 
resource limited settings, optimal adherence is critically important. Patients switched to second 
line ART for reasons other than non-adherence to first line appear to be about twice as likely to 
achieve viral suppression, suggesting that adherence during first line therapy may be an 
important indicator of adherence during second line therapy.2 Patients who were non-adherent 
during firs line therapy may also be non-adherent during second line therapy. If true, targeted 
intervention could be implemented for these patients prior to switching to second line therapy in 
order to improve patients’ outcomes. 
Timing of switching into second line therapy after first line failure is another target for 
possible intervention to improve patient’s outcomes, particularly in programs using 
immunological failure criteria. Given the relatively poor specificity and positive predictive values 
of immunological failure criteria in predicting virological failure, many patients with good 
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treatment success on first line therapy are misclassified as treatment failures.9,10 Due to the 
potential of misclassification, physicians delay in deciding when to switch; however, delayed 
switching is associated with high mortality.11 Delayed switching may also pose the risk of 
opportunistic infections among those experiencing unrecognized treatment failures. The 
magnitude of delay switching on the risk of opportunistic infections in this subset of population 
meeting immunological failure criteria is unknown. Due to the absence of future treatment 
options, exploring adherence and impact of switching times on the risk of opportunistic 
infections is vital in informing physician’s decision making to improve patient’s outcome. 
In this study, we assessed the effect of pre-switch adherence on post-switch adherence 
among second-line users. We also evaluated the effect of delay in switching and causal impact 
of switching among patients eligible to second-line by immunological failure criteria on the risk of 
opportunistic infections. To do this we used prospectively collected clinical data from Kilimanjaro 
Christian Medical Centre (KCMC), Mawenzi Regional Hospital (MRH), Kilema, Kibosho and 
Machame infectious disease clinics. 
AIM 1: To assess the association of adherence to first-line ART with adherence to 
second-line ART.  
Overview: The primary outcome is the percentage of self-reported adherence to second-
line ART. Optimal and suboptimal adherence was defined as percentage adherence of (≥ 90%) 
and (< 90%) respectively. Binomial regression models were used to assess the association of 
adherence to first-line ART with adherence to second-line ART. I hypothesized that patients 
who had suboptimal adherence (< 90%) prior to switch to second-line will have a higher 
proportion of suboptimal adherence after switching than those who had optimal (≥ 90%) 




AIM 2A: Among patients eligible for second-line by immunological failure criteria, 
what is the effect of immediate versus delayed (≥ 3 months) switching to second-line on 
the incidence of opportunistic infections? 
 Overview: The primary outcome is time from immunological failure to the first 
occurrence of opportunistic infections tuberculosis (TB), pneumonia, Kaposi’s sarcoma (KS), 
cryptococcal meningitis (CM), herpes zoster).12 Cox proportional hazards marginal structural 
models (MSM) were used to assess the differences of time to the first occurrence of 
opportunistic infections by switching status. I hypothesized that among patients eligible for 
second-line by immunological failure criteria, delayed switching to second-line would result into 
a higher incidence of opportunistic infections compared to immediate switching. 
AIM 2B: Among patients eligible for second-line by immunological failure criteria 
what is the effect of switching to second-line on the incidence of opportunistic 
infections?  
Overview: The primary outcome is time from immunological failure to the first occurrence 
of opportunistic infections (tuberculosis, pneumonia, Kaposi’s sarcoma, cryptococcal meningitis, 
herpes zoster).12 Cox proportional hazards marginal structural models (MSM) were used to 
assess the differences of time to the first occurrence of opportunistic infections by switching 
status. I hypothesized that among patients eligible for second-line by immunological failure 
criteria, switching to second-line would result into a lower incidence of opportunistic infections 
compared to those who continued with the failed regimen.
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
 High potency of second line ART revealed early good treatment outcomes among HIV-
infected adults failing first line ART.2,11 Most patients switched to second line ART have 
undetectable viral load and improved immunity at 6 and 12 months of follow up.6,13 Despite good 
treatment success in many patients, some patients are failing relatively quickly, suggesting 
medication non-adherence may be a major concern.13-15 Realizing second line therapy is the 
last treatment option in many parts of resource limited settings, maximizing its potential benefits 
by addressing adherence and switching times in these settings is vitally important. 
Adherence during first line ART may be an important predictor of adherence during 
second line ART. Sub-optimal adherence in first line ART has been associated with stigma, low 
social economic status, and long travel distances to the care sites. Provision of free ART and 
decentralization of ART programs from referral hospitals to health care centers was 
implemented to improve adherence in many resource limited settings. Despite these efforts, 
some second-line users are still non-adherent.5,6,16 Patients switched to second line because of 
medication non-adherence were less likely to achieve viral suppression. Since success of 
second line ART depends on high levels of adherence, such an observation may suggest 
adherence on first line may be an important indicator of adherence during second line.2,14 Since 
whether individuals who were non-adherent prior to their switch continue to be non-adherent 
after switching to second-line ART is unclear, evaluating the association of adherence to first 
line ART with adherence to second line ART is critical. The findings may help identify this group 
of patients and calls for targeted intervention prior to their switching into second line therapy in 
order to improve their outcomes. 
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Times to switch into second line therapy is another hurdle in the success of second line 
ART. Lack of routine virological monitoring systems in many parts of resource limited settings 
causes switching times to vary substantially.5,16-18 Physicians are reluctant to switch patients to 
second line because the decision on when to switch is based on relatively poorly performing 
immunological failure criteria. The longer the time patients remain on failed regimen, the longer 
they may take to have immunity recovery and be virologically suppressed after switching to 
second line therapy.19 As a consequence of delayed switching, patients with unrecognized 
treatment failure may develop opportunistic infections. Delayed switching is associated with 
increased risk of mortality.11 Although causes of deaths were not described, some patients 
might have had opportunistic infections prior to death. The importance of switching to second 
line immediately after the diagnosis of treatment failure is made was also evidenced in program 
with biannual routine viral load monitoring. Patients switched after the first detectable viral load 
(HIV RNA ≥ 1000c/ml) are more likely to achieve viral suppression than those switched after a 
second detectable viral load.2 Substantial variation on switching times calls for further evaluation 
to explore the impact it may have on the risk of opportunistic infections. 
Generally, most of the studies on second line ART in resource limited settings were 
done in South Africa where patients are routinely monitored using HIV RNA testing. In addition, 
these studies were done when a few patients were initiated second line ART and therefore their 
sample sizes are relatively small. Furthermore, the causal effect of switching on the risk of 
opportunistic infections among patients meeting immunological failure criteria has never been 
evaluated. We therefore evaluated the association of adherence to first line ART and adherence 
to second-line. In addition, we explored the effect of delayed switching and the causal effect of 
switching on the risk of opportunistic infections among patients meeting immunological failure 
criteria in northern Tanzania.  This study analyzed data collected from KCMC, Mawenzi, Kilema, 
Kibosho and Machame Hospitals, which are located within Moshi Municipality. According to 
hierarchy of Tanzania health care delivery systems, these hospitals take the first three positions 
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as referral and regional and district hospitals. All hospitals have access to CD4 cell count 
testing, and therefore are ideal places for this study. 
ART uptake and adherence 
In 2011, approximately 1.6 million Tanzanians were living with HIV and an estimated 
660,000 persons are in need of ART.20 Forty one percent of those in need were receiving ART, 
equivalent to an eight percent increase compared to 2009. In 2004 before ART were made 
freely available, about 1.4 million persons were estimated to live with HIV, however, fewer than 
5000 persons were receiving ART. An increase ART coverage rate was facilitated by 
international donor supports.  Early in 2005, at the time of transitioning to free ART 
approximately 84% of adults were reported to have 100% adherence (not missing any dose in 
the last 3 days) in northern part of Tanzania.21 Due to the variability of adherence 
measurements, other studies reported adherence of up to 96% in later years.22,23 Information 
about adherence to ART after decentralization of ART programs is limited in this region; 
however, adherence is expected to have improved. 
Adherence measurements 
Various methods of medication adherence assessments have been developed. The 
methods include measuring plasma concentration levels of medications, Medication Event 
Monitoring System (MEMS), pill count, pharmacy records, self-report questionnaires and visual 
analogue scale (VAS).21,24-27 Other than plasma drug concentration, none of the remaining 
methods is superior. For example, MEMS caps measure the number of times medication bottle 
is open to indicate the patient has taken his/her pill. Neither a missing pill in pill count nor an 
opened medication bottle necessarily indicates that the patient has taken his/her medication.28-30 
In addition, self-report questionnaires and visual analogue scales are subject to recall bias. 
Logistical issues including technical expertise and costs associated with some adherence 
assessment methods impairs their extensive use in many parts of resource limited settings.31 
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Despite the deficiencies of adherence assessments methods, a majority of the patients 
reporting high level of adherence have undetectable viral load.21,32,33 
We chose to use self-reported adherence in this study.  Patients who failed first line ART 
by immunological failure criteria were interviewed by phone or in person. Several studies have 
documented an association between self-reports adherence and viral load, which suggests that 
self-reports, may be a valid indicator of adherence.21, 32 
Barriers to ART adherence and efforts to alleviate 
ART is a life-long treatment. Its success depends on sustained medication use. The 
main concern of the interrupted medication use is the development and the spread of resistant 
strains of viruses leading to treatment failure.34,35 Many challenges arose when ART became 
available for treatment of HIV-infected patients. Among the challenges associated with 
treatment adherence are poverty, stigma associated with HIV infection, long distance travelled 
to clinics, long waiting hours at the clinic, attitude of the health care workers, substance abuse, 
forgetfulness, being away from home, side effects etc. 
Poverty 
Financial constraints have been constantly reported to be associated with treatment 
interruptions.21,35 Due to the expenses of purchasing ART medications, few patients were able 
to continually purchase them. In one study, evaluating risk factors of medication non-adherence 
at the time when ART was not extensively made free of charge, we asked patients if they had 
moments spending the money they needed for health care for something else such as paying 
house rent etc. A substantial proportion of participants agreed to have sacrificed health care for 
other necessities, suggesting financial constraint as the risk factor of medication non-
adherence. Cost associated with long distance travelled to the clinics for regular appointments 
has also been documented as the reason for medication non-adherence.36,37 
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Recognizing the consequences of medication non-adherence, through donor support, 
interventions to make ART accessible to people with different economic status were 
implemented. First, formulations of generic medication by pharmaceutical companies have 
lowered the cost of ART.38 Secondly, in many parts of resource limited settings, ART was made 
free of charge.23,39 Moreover, ART care and treatment programs have been decentralized from 
consultant and regional hospitals to district and health care centers in order to minimize the 
travelling costs.40-43 Decentralization of ART programs also reduced long waiting hours as 
patients have options to attend various infectious disease clinics. 
Stigma associated with HIV 
Fear of discrimination by the family members of community impaired HIV-infected 
patients to disclose their HIV status and negatively impacts ART medication use.21,44 Earlier on 
it was hoped that increased access to ART would turn HIV/AIDS into a more manageable 
condition and consequently reduce stigma. While this is the case in some parts of world, stigma 
still persist in many resource limited settings. Efforts to reduce stigma have also included 
improvement of clinical services, bolstering of health care providers morale, and community 
health education about HIV. 
Adherence as the salvage intervention 
The use of immunological failure criteria in identifying treatment failure, lack of 
resistance testing and limited availability of second line ART makes targeted adherence as the 
main salvage intervention of improving patient’s outcome. Medication non-adherence among 
patients receiving first line ART proved to be associated with treatment failure as a 
consequence a number of patients failing first line ART switch to second line.45,46 In resource 
limited settings, diagnosis of treatment failure is often late due to the lack of routine viral load 
testing. Most patients failing first line ART have accumulated resistance mutations.1,8,21,47,48 The 
accumulated resistance mutations following medication non-adherence and delayed switching is 
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considered to have negative impacts on the outcome of patients receiving second line.19 In 
addition to the resistance mutation patients might have accumulated following first line treatment 
failure, medication non-adherence may persist and negatively impact patient outcome among 
second line users.5,6,49 
Many ART programs have addressed and implemented adherence support 
mechanisms. Despite these efforts, for unknown reasons some patients receiving second line 
ART are still non-adherent.46 A few treatment sites have third line ART options in resource 
limited settings and patient failing second line will still be kept on failed regime.15 To maximize 
potential benefits of high potency second line ART, further evaluation of predictors of medication 
non-adherence is critical. Whether patients who were not optimally adherent during first line 
continue to be non-adherent during second line is unknown. If this relationship exists, limited 
treatment options calls for identification of this subgroup of patients who might benefit from 
targeted adherence support mechanisms that involves, in addition to routine counseling, HIV 
education sessions for patients and family members, and possibly supervisory home-based 
care that proved to improve adherence elsewhere.50 Although home-based care seemed 
challenging due to shortage of staff and long distance to patient’s premises, its implementation 
may not be in demand in these moments when treatment and care programs have been 
decentralized. 
Magnitude of opportunistic infections 
Patients failing first line ART may be as equally at risk of acquiring opportunistic 
infections as those not initiated on ART. Opportunistic infections such as TB, pneumonia, KS, 
herpes zoster and CM are significant contributors of morbidity and mortality among HIV-infected 






Pulmonary TB is one of the principal causes of death of the infectious diseases among 
HIV-infected adults in resource limited settings and the disproportionate burden of the disease is 
seen in this region. Annual notification rate of TB in sub-Saharan Africa has been on the rise 
since 1980’s.51 It is not surprising the increase in the number of TB cases is related to HIV 
infections. In Tanzania, the annual cumulative incidence of TB was 107 cases per 100,000 
populations in 1990 (figure 2.3). The cumulative incidence increased by approximately 69% in 
2004 suggesting that TB is still a huge concern in the country. Despite poor sensitivity of 
microscopic examination of the sputum in the diagnosis of TB, a combination of chest x-ray and 
sputum culture improved the diagnosis. Reported prevalence of TB among patients attending 
infectious disease clinics ranged from (7.2 – 21.6) percent.52,53 Compared to HIV-infected adults 
with CD4+ cell > 200 cell/ mm3, those with CD4+ cell less than 200 cell/mm3 were more likely to 
have TB.53 Since severe immunosuppression is a risk factor of developing TB, it is likely that 
individuals failing first line ART may also be at risk of acquiring TB. 
Cryptococcus meningitis (CM) 
CM is one of the most lethal opportunistic infection among HIV-infected patients. 
Compared to developed countries, sub-Saharan Africa bears a high burden with estimated 
annual incidence of 720,000 cases.54 The reported prevalence of CM among admitted HIV-
infected adults and among HIV-infected adults presented with headache and altered mental 
status in Tanzania were 4.4 and 26.8 percent respectively.55 Severe immunosuppression 
defined by a CD4+ cell less than 100 cells / mm3 is predictive of CM. Since some of the patients 
meeting immunological failure criteria might have persistently low CD4+ cell below 100 cells 
/mm3, it is likely that these patients are at risk of acquiring CM. In addition, due to the delay in 
the diagnosis, up to about 70% of the patients diagnosed with CM in resource limited settings 




Pneumocystis pneumonia (PCP) 
PCP is another respiratory illness commonly observed in HIV-infected patients. In many 
African countries, the prevalence of PCP is estimated to be as high as 27 %.56 Lack of sensitive 
diagnostic equipment in diagnosing PCP probably underestimate  the magnitude of PCP in this 
region. Prevalence of PCP in Tanzania is similar to those reported in other resource limited 
settings. Among HIV-infected patients presented with cough in two tertiary hospitals, the 
prevalence of PCP was 7.5 and 10.4 percent respectively.52,53 In the developed world, the 
median CD4+ cell count among patients on HAART diagnosed with PCP is 29 cell/ mm3 
compared to 13 cell/ mm3 among those not on HAART, suggesting that very low CD4+ cell 
count may be associated with the development of PCP.57 
Kaposi’s sarcoma (KS) 
Of the malignancies affecting HIV-infected patients, KS is the most commonly observed. 
In a study evaluating the impact of HAART on the incidence of KS, incidence densities among 
ART naïve patients were 1876, 596 and 624 per 100,000 person-years in Kenya, Uganda and 
Southern Africa respectively. The corresponding incidence densities among patients on HAART 
were 201, 270 and 174.58 Although these findings suggest significant reduction on the incidence 
of KS, the magnitude of KS among patients failing first line ART is not known. The prevalence of 
KS among 700 biopsies of oral lesion in Tanzania was 11.1 % of which 95% were associated 
with HIV.59 
Herpes zoster 
One of the common dermatological manifestations of HIV-infected patients in resource 
limited settings is development of herpes zoster. Almost all young adults diagnosed with herpes 
zoster are HIV co-infected. In the pre-ART era, the prevalence of herpes zoster among 
infectious disease clinic attendees in Tanzania was about 26%.60 The incidence of herpes 
zoster after the introduction of free ART in this region is unknown. Herpes zoster is associated 
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with severe morbidity and hence exploring its magnitude among patients failing first line ART is 
critical.61 
Delayed switching and possible risk of opportunistic infections 
Identification and management of the patients failing first line ART remained to be a 
challenge in resource limited settings. Although viral load testing is a gold standard for 
identification of treatment failure, it is not available, and if available is not for routine use in many 
parts of resource limited settings.18,62-64 As a consequence, ART programs in these settings use 
WHO algorithm to identify treatment failure. The accuracy of WHO criteria in identifying 
treatment failure is questionable. The reported ranges of sensitivities and positive predictive 
values are (16 – 58) and (21– 54) percent respectively.10,65-67 Low sensitivities suggest that a 
high proportion of patients that should have been switched to second line remained on failed 
regimen while low positive predictive value suggest a high proportion of patients that should not 
have been switched to second line, switched unnecessarily. Due to these unintended 
misclassifications and to maximize the potential benefits of more affordable fist line ART; health 
care providers are reluctant to switch patients on second line immediately after the diagnosis of 
treatment failure is made.11 Low rates of switching into second line (0.5 – 3.3) per 100 person-
years further justifies physician’s reluctance.18,68,69 Lack of viral suppression (HIV RNA > 400 
c/ml) was seen for each additional month in delaying switching.19 It is therefore likely that 
delayed switching may lead to the occurrence in patients with unrecognized treatment failure 
the opportunistic infections.  Diagnosis of treatment failure by using WHO immunological failure 
criteria is associated with higher levels of HIV RNA and multi nucleoside/nucleotide resistance 
mutation.46,70 High levels of HIV RNA is suggestive of continuing viral replication among patients 
on failed first line regimen. Continued viral replication further poses a risk of opportunistic 
infection in these patients. Moreover, since standard second line ART includes in addition to 
boosted protease inhibitors the nucleoside/nucleotide reverse transcriptase inhibitors, a class of 
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medication that was also used during first line, the effectiveness of second line ART may also 
be compromised. 
Compared to patients meeting WHO immunological failure criteria and switched to 
second line ART, patients who met WHO immunological failure criteria and remained on first 
line ART were more likely to die.63 Although these findings are critical to inform physician 
decisions on whether to switch patients meeting immunological failure criteria, the study has 
methodological issues. Patients who switched were more likely to be severely immune 
compromised than those who did not switch as indicated by the median CD4+ cell count at the 
time of switch of 82 c/mm3 and 174 c/mm3 respectively. Since switching was influenced by 
CD4+ cell, confounding by indication is a potential problem. In this study, we will assess the 
causal effect of switching on the risk of opportunistic infections using marginal structural models 
that take care of confounding by indication.71 
Due to the relatively poor performance of immunological failure criteria in identifying 
treatment failure, physicians may find delayed switching of patients to second line to be 
beneficial for the sake of preserving current treatment options, avoiding exposing patients to 
more toxic second line, and minimizing the cost of managing toxic effects. However, patients 
with true treatment failure may develop opportunistic infections. 
With these remarks, we explored the impact of delayed switching and the causal effect 
of switching to second line on the risk of opportunistic infection among patients meeting 
immunological failure criteria. We believe our findings will add to the existing knowledge the 
effects of switching times and risk of opportunistic infection as well as informing physician’s 





Figure 2.1: Trend in the number of people living with HIV since 1990 
  
 
Figure 2.2: ART coverage rate: Percent of those receiving ART to those in need 




Figure 2.3: Trends in TB incidence in Tanzania 
Source: Ministry of Health and Social Welfare 
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CHAPTER 3: RESEARCH DESIGN AND METHODS 
Overview 
For our first aim, which explores the association between adherence to first-line ART 
and adherence to second-line ART, we conducted a cross-sectional study among HIV-infected 
patients switched to second-line ART. In our second aim that explores switching and delayed 
switching to second-line ART on the risk of opportunistic infections, we abstracted data from 
patient’s medical records. 
Aim 1: Adherence to antiretroviral therapy  
To assess the association of adherence to first-line ART with the adherence to second-line 
ART. 
Study population 
The study population consisted of HIV-infected adolescent and adult patients attending 
CTC’s at the Kilimanjaro Christian Medical Center (KCMC), Mawenzi Regional Hospital (MRH), 
and Kibosho, Kilema and Machame Hospitals in Northern Tanzania between January 2004 and 
August 2013. According to the hierarchy of Tanzania health system, KCMC is a tertiary referral 
hospital, MRH is a regional hospital, and Kibosho, Kilema and Machame serve as district 
hospitals. These CTC’s offer treatment according to the Tanzanian Ministry of Health treatment 
guidelines for the provision of ART. Patients received fixed-dose combination of stavudine, 
lamivudine and nevirapine (D4T/3TC/NVP) as first-line ART. Zidovudine (AZT) and efavirenz 
(EVF) were used in place of D4T and NVP respectively, depending upon toxicities and 
concurrent medications. Each patient was seen on a monthly basis and their prescriptions were 
refilled at each visit. At the time of this study, routine viral load monitoring was not available in 
these CTC’s; therefore, patients were switched to second-line ART based on clinical and 
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immunological criteria according to WHO Guidelines.72 We used immunological failure criteria to 
identify study participant.
The drugs used for second-line ART included tenofovir, abacavir and lopinavir/ritonavir; 
atazanavir/ritonavir (ATZ/r) was substituted for LPV/r as needed.
The second-line nucleoside reverse transcriptase inhibitor (NRTI) choice for adolescents and 
adults depended on the first-line ART. For patients on AZT or D4T in first-line ART, the default 
second-line option was TDF combined with 3TC or FTC and LPV/r. For those who had received 
TDF in first-line, the second-line option was an AZT-based regimen. For those who were on 
TDF during first-line because of intolerance to AZT or D4T, an alternative second-line option 
was abacavir (ABC) combined with 3TC or FTC and LPV/r. Patients who were less than 13 
years old were excluded. 
The prevalence of HIV infection in 2008 among individuals attending voluntary and 
testing counseling centers (VCT) in this region was 4.3% and 5.8% for men and women 
respectively. The lower prevalence of HIV in men may be attributed to the low number of men 
testing compared to women due to stigma reasons that seem to affect more men than women. 
The overall prevalence of HIV infection in the country is estimated to be (5.1) %. Given that the 
overall prevalence of HIV infection in Kilimanjaro region is not very different from that of the 
country and all patients receive free ART throughout the country, then this was an ideal study 
population for our study. 
Outcome 
The primary endpoint was the cumulative percentage adherence to second-line ART. 
We defined optimal and suboptimal adherence as percentage of self-reported cumulative 
adherence of ≥ 90% and < 90% respectively. A cut off of 90% was chosen for two reasons: first, 
we assessed cumulative adherence as opposed to 3 -day recall, which would normally result in 
higher adherence percentages; and secondly, a previous study showed that variation in plasma 
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viral load is not increased when adherence is between 90% and 100%; however, adherence 
below 90% had a significant effect in terms of plasma viral load.73  
Exposure 
The exposure of interest was the cumulative percentage adherence to first-line ART. 
Optimal and suboptimal adherences were defined as the percentage of self-reported cumulative 
adherence of ≥ 90% and < 90% respectively. 
Other covariates 
Other variables evaluated were age, gender, duration on first-line ART, treatment sites, 
CD4 cell count at the time of treatment initiation, CD4 cell count at time of switch, and the 
patient’s weight. Patient date of birth was used to compute age in years which was categorized 
as (age < 30, 30 – 55 and > 55). Duration on first-line line was calculated in months and 
categorized as (duration < 36, 36 – 60 and > 60). Patient’s weights were measured in kilograms 
(kg) and categorized as (weight < 45, 45 – 70 and > 70). Sites were categorized as KCMC, 
Mawenzi and others. CD4 cell counts were measured in c/mm3 and were dichotomized as (< 
200 and ≥ 200).Gender was assessed as male or female. 
Data analysis 
Statistical analyses were conducted using Statistical Analysis Software (SAS) version 
9.3. Institute Inc., Cary, NC, USA. The distribution of continuous variables was explored to 
decide whether or not to categorize. Frequencies of categorical variables were calculated as the 
proportions of patients sampled. Crude and adjusted binomial regression models were used to 
assess the association of adherence to first-line ART with adherence to second-line ART. All 
associations were presented as adjusted prevalence ratios (APRs) with 95% confidence 
intervals (CI).Estimates whose confidence intervals excluded 1, were considered statistically 
significant. The final multivariate model included established demographic and clinical factors 
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associated with adherence. Sensitivity analyses were performed with adherence redefined at 
85% and 95% cutoffs. 
Aim 2: Switching and risk of opportunistic infections 
2a. Among patients eligible for second-line by immunological failure criteria, what is the effect of 
immediate versus delayed (≥ 3 months) switching to second-line on the incidence of 
opportunistic infections. 
Study population 
The study population consisted of 396 HIV-infected adolescent and adult patients 
receiving second-line ART from CTC’s at the Kilimanjaro Christian Medical Center (KCMC), 
Mawenzi Regional Hospital (MRH), and Kibosho, Kilema and Machame Hospitals in Northern 
Tanzania between January 2004 and August 2013. 
The drugs used for second-line ART included tenofovir, abacavir and lopinavir/ritonavir; 
atazanavir/ritonavir (ATZ/r) was substituted for LPV/r as needed. The second-line nucleoside 
reverse transcriptase inhibitor (NRTI) choice for adolescents and adults depended on the first-
line ART. For patients on AZT or D4T in first-line ART, the default second-line option was TDF 
combined with 3TC or FTC and LPV/r. For those who had received TDF in first-line, the second-
line option was an AZT-based regimen. For those who were on TDF during first-line because of 
intolerance to AZT or D4T, an alternative second-line option was abacavir (ABC) combined with 
3TC or FTC and LPV/r. Patients who were less than 13 years old were excluded. 
Outcome 
The primary end point was the time from immunological failure to the first occurrence of 
opportunistic infections [tuberculosis (TB), pneumonia, Kaposi’s sarcoma (KS), cryptococcal 
meningitis (CM) and herpes zoster (HZ)]. Time of immunological failure began at the visit when 
the failure diagnosis was made. All TB, KS, CM and some pneumonia infections were confirmed 
by the laboratory, histopathology or x-ray, while herpes zoster infections were diagnosed 
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clinically. We defined loss to follow-up as the absence of a documented clinic visit six months 
from date of the previous clinic visit. 
Exposure 
The exposure of interest was delayed switching to second-line ART. We defined 
immediate and delayed switching if switching happens at < 3 months and ≥ 3 months 
respectively the diagnosis of immunological failure was made. A cut-off of 3 months was chosen 
because following a failure diagnosis; patients receive 1-2 months of intensive adherence 
counselling prior to making the switch. 
Other covariates 
Other variables evaluated were age, gender, duration on first-line ART, treatment sites, 
adherence to first and second-line ART. Patient date of birth was used to compute age in years 
which was categorized as (age < 30, 30 – 55 and > 55). Duration on first-line was calculated in 
months and categorized as (duration < 36, 36 – 60 and > 60).Adherence to ART was measured 
in percentage and dichotomized as suboptimal (< 90%) and optimal (≥ 90%). Sites were 
categorized as tertiary, regional and district hospitals. Gender was assessed as male or female. 
Data analysis 
Cox proportional hazards marginal structural models were used to assess the 
differences of time to the first occurrence of opportunistic infections by switching status. 
Sensitivity analysis was performed by defining time from failure diagnosis to death or first 
occurrence of opportunistic infections as the outcome.  
2b. Among patients eligible for second-line by immunological failure criteria what is the causal 
effect of switching to second-line on the incidence of opportunistic infections? 
Study population 
The study population consisted of 637 HIV-infected adolescent and adult patients who 
met WHO immunological failure criteria from CTC’s at the Kilimanjaro Christian Medical Center 
 21 
 
(KCMC), Mawenzi Regional Hospital (MRH), and Kibosho, Kilema and Machame Hospitals in 
Northern Tanzania between January 2004 and August 2013. 
Outcome 
The primary end point was the time from immunological failure to the first occurrence of 
opportunistic infections [tuberculosis (TB), pneumonia, Kaposi’s sarcoma (KS), cryptococcal 
meningitis (CM) and herpes zoster (HZ)]. 
Exposure 
The exposure of interest was time until switching to second-line ART. We defined 
switched to second-line as initiation of a boosted PI-based regimen; otherwise, the patient was 
considered not switched. 
Other covariates 
Other variables evaluated were age, gender, duration on first-line ART, treatment sites, 
adherence to first and second-line ART. Patient date of birth was used to compute age in years 
which was categorized as (age < 30, 30 – 55 and > 55). Duration on first-line was calculated in 
months and categorized as (duration < 36, 36 – 60 and > 60).Adherence to ART was measured 
in percentage and dichotomized as suboptimal (< 90%) and optimal (≥ 90%). Sites were 
categorized as tertiary, regional and district hospitals. Gender was assessed as male or female. 
Data analysis 
Cox proportional hazards marginal structural models were used to assess the 
differences of time to the first occurrence of opportunistic infections by switching status. 
Sensitivity analysis was performed by using propensity scores weighting to assess the effect of 
switching to second-line ART on the risk of opportunistic infections. In this case the main 
exposure switching to second-line ART was considered as time fixed mimicking the design of 
randomized controlled trial where every eligible patient would be assigned either to be switched 
or not at baseline.
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CHAPTER 4: ASSOCIATION OF FIRST-LINE ANTIRETROVIRAL THERAPY ADHERENCE 
WITH ADHERENCE TO SECOND-LINE ANTIRETROVIRAL THERAPY AMONG HIV-
INFECTED PATIENTS IN TANZANIA. 
Introduction 
Global efforts towards universal access to antiretroviral treatment (ART) have led to an 
increase in the number of patients receiving ART in low- and middle-income countries (LMIC).73 
ART coverage rose from about 3 million persons in 2007 to 9.7 million in 2012.19,74 Although 
clinical, immunological and virological outcomes of the HIV-infected patients receiving first-line 
ART are promising,69,75-79, many patients are failing first-line and requiring a switch to second-
line ART.2 About 6% of patients receiving first-line therapy in sub-Saharan Africa need to switch 
to second-line regimens in any given year.74 For patients failing first-line ART, the World Health 
Organization (WHO) recommends switching from non-nucleoside reverse transcriptase inhibitor 
(NNRTI)-based regimens to protease inhibitor (PI)-based regimens. Most patients switched to 
second-line PI-based regimens experience good early treatment outcomes 2,11, with 
undetectable viral load and increased CD4 counts after 6 and 12 months of follow-up.6,14 
Despite treatment success in many patients on second-line ART, some patients fail relatively 
quickly; an estimated 33% – 40% of patients receiving second-line ART are failing,8,80 potentially 
due to medication non-adherence.13,16 
Medication non-adherence in first-line ART has been associated with stigma, food 
insecurity, low socioeconomic status, and long travel distances to the care sites.21,26,36 Provision 
of free ART and decentralization of ART programs from referral hospitals to health care centers 
has been implemented in an attempt to improve adherence in many LMIC. Despite these 
efforts, some second-line users are still non-adherent.5,6,16 Patients switched to second-line 
because of medication non-adherence were less likely to achieve viral suppression.14 
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Due to the apparent high genetic barrier to resistance mutations in patients receiving 
boosted PIs,80,81 most patients failing PI-based second-line regimens do not have PI resistance 
mutations, suggesting that non-adherence may be the main reason for treatment failure. 14,80,82 
Moreover, compared to patients who switched to second-line due to accumulated resistant 
viruses, those who switched with wild type viruses were less likely to achieve viral 
suppression.14 This observation may also suggest that medication non-adherence is responsible 
for treatment failure among patients switched into second-line ART. Since success of second-
line ART depends on high levels of adherence, these observations imply that adherence on 
first-line may be an important indicator of adherence to second-line ART.2,13 If true, targeted 
interventions could be implemented for these patients prior to switching to second-line therapy, 
and may improve patient outcomes. 
Whether individuals who were non-adherent prior to their switch continue to be non-
adherent after switching to second-line ART is unclear. Thus, evaluating the association of 
adherence to first-line ART with adherence to second-line ART is critical. Furthermore, second-
line ART is associated with higher costs, and second-line ART is the final salvage regimen in 
many LMIC, underscoring the need for evaluation.80 We used cross-sectional survey data and 
linked it with prospectively collected clinical data from five care and treatment centers (CTC) 
located in northern Tanzania to assess the effect of adherence to first-line ART on the 
adherence to second-line ART. 
Methods 
Study design and population 
We used a cross-sectional study design to evaluate the association of adherence to first-
line ART with adherence to second-line ART. The study population consisted of all HIV-infected 
adolescent and adult patients on second-line ART attending CTC’s at the Kilimanjaro Christian 
Medical Center (KCMC), Mawenzi Regional Hospital (MRH), and Kibosho, Kilema and 
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Machame Hospitals in Northern Tanzania between January 2004 and August 2013. According 
to the hierarchy of Tanzania health system, KCMC is a tertiary referral hospital, MRH is a 
regional hospital, and Kibosho, Kilema and Machame serve as district hospitals. These CTC’s 
offer treatment according to the Tanzanian Ministry of Health treatment guidelines for the 
provision of ART. Patients received fixed-dose combination of stavudine, lamivudine and 
nevirapine (D4T/3TC/NVP) as first-line ART. Zidovudine (AZT) and efavirenz (EVF) were used 
in place of D4T and NVP respectively, depending upon toxicities and concurrent medications. 
Each patient was seen on a monthly basis and their prescriptions were refilled at each visit. At 
the time of this study, routine viral load monitoring was not available in these CTC’s; therefore, 
patients were switched to second-line ART based on clinical and immunological criteria 
according to WHO Guidelines.72 We used immunological failure criteria to identify study 
participants.  
The drugs used for second-line ART included tenofovir, abacavir and lopinavir/ritonavir; 
atazanavir/ritonavir (ATZ/r) was substituted for LPV/r as needed. The second-line nucleoside 
reverse transcriptase inhibitor (NRTI) choice for adolescents and adults depended on the first-
line ART. For patients on AZT or D4T in first-line ART, the default second-line option was TDF 
combined with 3TC or FTC and LPV/r. For those who had received TDF in first-line, the second-
line option was an AZT-based regimen. For those who were on TDF during first-line because of 
intolerance to AZT or D4T, an alternative second-line option was abacavir (ABC) combined with 
3TC or FTC and LPV/r. Patients who were less than 13 years old were excluded. 
Data collection 
After obtaining informed consent, standardized questionnaires translated into Kiswahili 
were administered to participating patients by trained research nurses. Those who were not 
captured at their CTC’s were interviewed by telephone. The questionnaire addressed 
demographic characteristics and the patient’s adherence before and after switching to second-
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line ART. Using a visual analogue scale, participating patients were asked to rate their 
adherence percentages before and after switching to second-line therapy.  
 As part of routine HIV clinical care, all patient data including demographics, medication 
use, opportunistic infections, adherence indicators (adherent = fewer than 2 missed days per 
month/non-adherent = 2 or more missed days per month), and laboratory values were collected 
on standardized forms, and entered into a database designed and funded by Tanzanian 
National AIDS Control Program (NACP) in collaboration with Elizabeth Glacier Pediatric AIDS 
Foundation (EGPAF). This database was searched for clinical data, and when information was 
missing, it was abstracted from their respective medical files. Treatment monitoring included 
clinical and immunological criteria; CD4 cell counts were checked at 4-6 month intervals using 
flow cytometry.  
Definition of variables 
The primary endpoint was the cumulative percentage adherence to second-line ART. 
We defined optimal and suboptimal adherence as percentage of self-reported cumulative 
adherence of ≥ 90% and < 90% respectively. A cut off of 90% was chosen for two reasons: first, 
we assessed cumulative adherence as opposed to 3 -day recall, which would normally result in 
higher adherence percentages; and secondly, a previous study showed that variation in plasma 
viral load is not increased when adherence is between 90% and 100%; however, adherence 
below 90% had a significant effect in terms of plasma viral load.83  
The exposure of interest was the cumulative percentage adherence to first-line ART. 
Optimal and suboptimal adherences were defined as the percentage of self-reported cumulative 
adherence of ≥ 90% and < 90% respectively. Other variables evaluated were age, gender, 
duration on first-line ART, treatment sites, CD4 cell count at the time of treatment initiation, CD4 
cell count at time of switch, and the patient’s weight. 
Institutional review board (IRB) approval was obtained from the University of North 




Statistical analyses were conducted using Statistical Analysis Software (SAS) version 
9.3. Institute Inc., Cary, NC, USA. The distribution of continuous variables was explored to 
decide whether or not to categorize. Frequencies of categorical variables were calculated as the 
proportions of patients sampled. Crude and adjusted binomial regression models were used to 
assess the association of adherence to first-line ART with adherence to second-line ART. All 
associations were presented as adjusted prevalence ratios (APRs) with 95% confidence 
intervals (CI).Estimates whose confidence intervals excluded 1, were considered statistically 
significant. The final multivariate model included established demographic and clinical factors 
associated with adherence. Sensitivity analyses were performed with adherence redefined at 
85% and 95% cutoffs. 
Results 
From May through August 2013, 11,289 medical files were reviewed, and 656 (5.8%) 
identified patients who met WHO immunological failure criteria (Figure 4.1). Of these, 456 
(69.5%) switched to second-line ART. Of those switched to second-line 20 (4.4%) were children 
less than 13 years and were excluded. Among the 436 adolescent and adult patients on 
second-line ART, 279 (64%) were female, and 298 (68.4%) were between 30 and 55 years 
(Table 4.1). Suboptimal adherence on first-line ART was reported by 322 (73.9%) patients. Most 
(351; 80.5%) had CD4 cell counts less than 200 c/mm3 at ART initiation, and 378 (86.7%) had 
CD4 cell counts less than 200 c/mm3 at the time of switch. Slightly higher than half of patients 
(246; 54.4%) spent less than 36 months on first-line ART, and 270 (62%) came from tertiary 
referral hospital (KCMC) CTC. The majority (278; 63.8%) weighed between 45kg and 70kg. 
Suboptimal adherence. 
One hundred and thirty-four persons (30.7%) reported cumulative suboptimal adherence 
to second-line ART. Patients who had suboptimal adherence to first-line ART were much more 
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likely to have suboptimal adherence to second-line ART than those who had optimal adherence 
to first-line (PR 2.4, 95% CI 1.5 – 3.9; Table 4.2). In bivariable analyses, compared to patients 
who weighed less than 45kg, those  weighing above 70kg were less likely to have suboptimal 
adherence to second-line ART (PR 0.5, 95% CI 0.3 –1.0).  
After adjusting for age, gender, site, duration on first-line ART, weight, baseline CD4 cell 
count and the CD4 cell count at the time of switch, the effect of adherence to first-line ART on 
adherence to second-line ART persisted (APR 2.4, 95% CI 1.5 – 3.9; Table 4.2). The effect of 
adherence to first-line ART on adherence to second-line ART was substantially stronger than 
other available factors. Several factors showed positive, but relatively imprecise, associations 
with suboptimal adherence to second-line ART. For example, patients switched to second-line 
ART at CD4 cell count less than 200 c/mm3 were slightly more likely to report suboptimal 
adherence during second-line than those switched at CD4 cell count more than 200 c/mm3 
(APR 1.2, 95% CI 0. 7 – 1.9). Compared to patients switched into second-line at less than 3 
years on first-line, those switched into second-line ART after 5 years were slightly more likely to 
report suboptimal adherence (APR 1.2, 95% CI 0.8 – 1.8). Patients who weighed more than 
70kg continued to be less likely to demonstrate suboptimal adherence to second-line, (APR 0.6, 
95% CI 0.3 – 1.1). 
Sensitivity analyses 
When optimal and suboptimal adherence were defined as percentage of self-reported 
cumulative adherence of ≥ 95% and < 95% respectively, patients who had suboptimal 
adherence to first-line ART were more likely to have suboptimal adherence to second-line ART 
than those who had optimal adherence to first-line (APR 3.0, 95% CI 1.7 – 5.2; Table 4.3). 
Defining adherence at 85% cutoff, the effect of suboptimal adherence to first-line on suboptimal 




Following increased access to ART in LMIC, a substantial proportion of patients are 
failing first-line ART and need a switch to second-line ART. Non-adherence to second-line ART 
negatively affects its potential benefits.4-6,72 In this study, we have shown that adherence to first-
line ART is an important predictor of adherence to second-line ART among HIV-infected 
adolescents and adults attending five CTC’s in Northern Tanzania. Compared to patients 
reporting optimal adherence to first-line ART, patients with suboptimal adherence to first-line 
ART were 2.4 times more likely to report suboptimal adherence to second-line ART.  
An association between adherence to first-line and second-line ART has been reported 
in South Africa,14 in which the odds of >90% adherence to second-line ART was 2.5 times as 
high among patients whose adherence to first-line ART was above the median (67%) compared 
to those with first-line adherence below the median. These findings support our hypothesis that 
patients who are non-adherent to first-line ART are more likely to be non-adherent to second-
line.  
 Others have made similar observations using plasma viral load as the primary end 
point. For example, fifty-five percent of patients who had sub-therapeutic drug concentrations on 
first-line ART failed to achieve viral suppression on second-line ART.72 Compared to patients 
who switched into second-line for reasons other than non-adherence, those who switched for 
non-adherence reasons were less likely to achieve viral suppression.2,83 Patients who were non-
adherent on first-line likely continued to be non-adherent after switching into second-line ART, 
which explains treatment failure after switching.  
In this study, about 15% of patients who had optimal adherence to first-line ART had 
suboptimal adherence to second-line ART. A decline of medication adherence and adherence 
practices over time has been reported previously.84,85 Although 36% of our patients who had 
suboptimal adherence before switching continued to have suboptimal adherence after the 
switch, the proportion of optimal adherence increased after switching. This may reflect the role 
 29 
 
of current counseling efforts on the importance of regular and consistent use of medication. 
Using medication possession ratio as adherence assessment method, others have shown an 
increase in median adherence from less than 67% prior to switching to second-line to 92% 
twelve months post-switch.14 
Patients with low CD4 cell counts at the time of switch reported suboptimal adherence 
after switching. Low CD4 cell count values in these patients may be attributed to non-adherence 
before switching, and possibly these patients continued to be non-adherent after their switches. 
Our findings can be substantiated by previous studies demonstrating that low CD4 cell count at 
the time of switch was associated with virological failure and high mortality on second-line 
ART.16,49 
Our study does have a number of limitations. We used self-reported adherence to 
assess adherence to first and second line ART; however, self-reported adherence is subject to 
both correlation to recall bias and overestimation of adherence percentages.80,86 Although most 
patients were on first-line ART for less than three years, some spent more than five years. Since 
adherence assessment occurred after switching into second-line ART, correlation recall bias is 
a potential concern, and misclassification could be differential (patients may have overestimated 
both their first-line and second-line adherence to a similar extent). If most patients 
overestimated their adherence percentages, patients who had suboptimal adherence to second-
line would have reported optimal adherence; however, among patients who had suboptimal 
adherence to second-line, 87.3 % had suboptimal adherence to first-line ART. Given high 
sensitivity of first-line adherence in detecting second-line adherence, it is likely that 
overestimation was minimal. In addition, despite the anticipated bias and overestimations, self-
reported assessment has been used extensively and it has being shown to be associated with 
virological outcome. 87 
We used a cross-sectional design to assess cumulative self-reported adherence on both 
first-line and second-line ART, and hence failed to account for variation of adherence over time. 
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As noted previously, adherence and adherence practices may decline over time. For example, 
adherence may be high when patients are seriously ill. Regaining health may tempt people to 
engage into practices that may lower their adherence. Smoking and alcohol consumption are 
among notable practices resumed following recovery, which in turn lowered patients 
adherence.84 While 3-30 days recall can produce high levels of adherence,21 reported median 
life-time adherence was between 60% and 62%,88,89 suggesting change of adherence over time. 
The cross-sectional design of our study did not allow an assessment of the effect of adherence 
to first-line on adherence to second-line longitudinally.  
The standard of care guidelines changed over the study period of 9 years. For example, 
different antiretroviral drugs became available over time, which could have increased their 
tolerability, potentially improving adherence. Such a change might result in to higher adherence 
percentages, yet, about 31% of patients had second-line adherence below 90%. 
Conclusion 
This study reports adherence to first-line ART as an important predictor of adherence to second-
line ART. Although most patients with suboptimal adherence prior to switch had improved 
adherence after switch, a substantial proportion of patients reported suboptimal adherence after 
switching. Targeted adherence interventions are needed in patients with low levels of 




Table 4.1: Demographic and clinical characteristics of HIV-infected adolescents receiving second -line ART at five 
infectious disease clinics in Kilimanjaro Region, Moshi, Tanzania, 2004 – 2013. 
Characteristics 
All patients                
(n = 436) 
Optimal                         
Adherence to 
second-line ART 




(n = 134) 
Adherence to first-line ART                  Optimal 114 (26.1) 97 (32.1) 17 (12.7) 
                                                             Suboptimal 322 (73.9) 205 (67.9) 117(87.3) 
Age                                                       < 30 years 113 (25.9) 77 (25.5) 36 (26.9) 
                                                             30 – 55 years 298 (68.4) 207 (68.5) 91 (67.9) 
                                                             > 55 years 25 (5.7) 18 (6.0) 7 (5.2) 
Gender                                                 Male 157 (36.0) 106 (35.1) 51 (38.1) 
                                                             Female 279 (64.0) 196 (64.9) 83 (61.9) 
Duration on first-line ART                     < 36 months     246 (56.4) 172 (57.0) 74 (55.2) 
                                                             36 –  60 months 136 (31.2) 97 (32.1) 39 (29.1) 
                                                             > 60 months 54 (12.4) 33 (10.9) 21 (15.7) 
CD4 cell count at ART initiation           < 200 c/mm3 351 (80.5) 240 (79.5) 111 (82.8) 
                                                             ≥ 200 c/mm³ 85 (19.5) 62 (20.5) 23 (17.2) 
CD4 cell count at time of switch           < 200 c/mm3 378 (86.7) 258 (85.4) 120 (89.5) 
                                                             ≥ 200 c/mm³ 58 (13.3) 44 (14.6) 14 (10.5) 
Sites                                                     KCMC  270 (61.9) 190 (62.9) 80 (59.7) 
                                                             Mawenzi 100 (22.9) 66 (21.9) 34 (25.4) 
                                                             Others 66 (15.1) 46 (15.2) 20 (14.9) 
Weights                                                < 45 kg 94 (21.5) 65 (21.5) 29 (21.6) 
                                                             45 – 70 kg 278 (63.8) 184 (60.9) 94 (70.2) 
                                                             >  70 kg 64 (14.7) 53 (17.6) 11 (8.2) 




Table 4.2: Crude and Adjusted risk factors of suboptimal adherence to second-line ART among HIV-infected 
adolescents and adults at five infectious disease clinics in Kilimanjaro Region, Moshi, Tanzania, 2004 – 2013. 
Bivariable Analysis Multivariable Analysis 
Prevalence ratio                      
(95 % CI) 
Adjusted prevalence ratio    
(95 % CI) Variable 
Adherence to first-line ART                     Optimal 1 1 
                                                                Suboptimal 2.4 (1.5 – 3.9)   2.4 (1.5 – 3.9) 
Age                                                          < 30 years 1   1 
                                                                30 – 55 years 0.9 (0.7 – 1.3) 1.1 (0.7 – 1.5) 
                                                                > 55 years 0.9 (0.4 – 1.7)   1.0 (0.5 – 2.0) 
Gender                                                    Male 1 1 
                                                                Female 0.9 (0.7 – 1.2)   0.9 (0.7 – 1.2) 
Duration on first-line ART                        < 36 months     1 1 
                                                                36 –  60 months 1.0 (0.7 – 1.3)   1.0 (0.7 – 1.3) 
                                                                > 60 months 1.3 (0.9 – 1.9) 1.2 (0.8 – 1.8) 
CD4 cell count at ART initiation              < 200 c/mm3 1   1 
                                                                ≥ 200 c/mm³ 1.2 (0.8 – 1.7) 0.9 (0.6 – 1.3) 
CD4 cell count at time of switch              < 200 c/mm3 1   1 
                                                                ≥  200 c/mm³ 1.3 (0.8 – 2.1) 1.2 (0.7 – 1.9) 
Sites                                                        KCMC  1   1 
                                                                Mawenzi 1.1 (0.8 – 1.6) 1.0 (0.7 – 1.5) 
                                                                Others 1.0 (0.7 – 1.5)   1.0 (0.6 – 1.5) 
Weights                                                   < 45 kg 1 1 
                                                                45 – 70 kg 1.0 (0.8 – 1.5)   1.0 (0.6 – 1.5) 
                                                                >  70 kg 0.5 (0.3 – 1.0) 0.6 (0.3 – 1.1) 




Table 4.3: Sensitivity Analyses on the effect of adherence to first-line on adherence to second-line ART among HIV-
infected adolescents and adults at five infectious disease clinics in Kilimanjaro Region, Moshi, Tanzania, 2004 – 2013. 
Cutoffs 
Proportion of suboptimal adherence 
to second-line ART (%) 




Optimal                
Adherence to 
first-line ART 






85% 77/267 (28.8) 8/169 (4.7) 5.3 (2.8 – 9.9) 6.0 (3.08 – 12.2) 
95% 241/386 (62.4) 8/50 (16.0) 4.0 (2.1 – 7.5) 3.0 (1.7 – 5.2) 





Figure 4.1: Study flow diagram. Selection of HIV-infected adolescents and adults receiving second-line ART at five 




CHAPTER 5: THE EFFECT OF SWITCHING TO SECOND-LINE ANTIRETROVIRAL 
THERAPY ON THE RISK OF OPPORTUNISTIC INFECTIONS AMONG HIV-INFECTED 
PATIENTS IN NORTHERN TANZANIA. 
Introduction 
Diagnosis and treatment of the patients failing first-line ART in low- and middle-income 
countries (LMIC) remains challenging.17,90 Because of the lack of routine viral load monitoring, 
the definition of treatment failure to depends entirely on WHO clinical and immunological failure 
criteria.16,18,62 Due to the potential misclassification of treatment failure resulting from using 
these failure criteria,9,10,66,67 as well as, limited availability of treatment options, poor laboratory 
infrastructure, low health care provider confidence in making switches, and high costs of 
second-line ART, physicians are often reluctant16,18,91 to switch. One consequence of 
unrecognized treatment failures and/or delayed switches may be an increased risk of 
opportunistic infections. 
Delayed switching to second-line ART in programs without routine viral load monitoring 
is common. A higher proportion of patients remain on a failed first-line regimen in programs 
without routine viral load monitoring, as compared to those in programs with routine viral load 
monitoring.67 Less than 45% of patients meeting WHO immunological and clinical failure criteria 
are switched to second-line ART.63,92 The rate of switch is higher in Eastern Europe than  in 
sub-Saharan Africa,69 and the difference in the rates of switch is attributed to the lack of routine 
viral load monitoring in African programs. A delay in switching is also indicated by the variation 
in switching times from failure diagnosis.17,69 The range of time from failure diagnosis to switch 
in programs without routine viral load monitoring is 2-15 months.63 In addition, in resource-
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limited settings, switching happens earlier in programs with routine viral load monitoring than in 
those without.93 
Despite treatment success for many patients on second-line ART, mortality and 
virological failure rates are high.6,14,19,69,80 Virological failure is defined as increasing levels of 
detectable HIV RNA and is associated with multiple nucleoside/nucleotide resistance 
mutations.45,70 Higher levels of HIV RNA pose the risk of opportunistic infections. Other than 
medication non-adherence, high mortality and treatment failure may also be due to delayed 
switching among patients with unrecognized treatment failure. Compared to patients meeting 
clinical/immunological failure criteria and switched into second-line ART, those who met criteria 
and did not switch had poor survival.63  
Reports about the frequency of opportunistic infections among patients failing first-line 
ART in LMIC are limited. Whether disproportionally higher opportunistic infections are observed 
in patients remaining on failed first-line regimen compared to those who switched to second-line 
ART is not understood. We sought to explore the influence of switching and delayed switching 
to second-line ART on the risk of opportunistic infections among patients meeting 
immunological failure criteria. 
Methods 
Study design and population. 
We used a retrospective cohort study design to evaluate the effect of switching to 
second-line antiretroviral therapy on the incidence of opportunistic infections among HIV-
infected patients in Northern Tanzania. Records of patients attending the Kilimanjaro Christian 
Medical Centre (KCMC), Mawenzi Regional Hospital (MRH), Kibosho, Kilema and Machame 
Hospitals between January 2004 and August 2013 were reviewed. Patients who were less than 
13 years old were excluded. According to the hierarchy of the health system in Tanzania, KCMC 
is a tertiary referral hospital, MRH is a regional hospital, and Kibosho, Kilema and Machame are 
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district hospitals. These care and treatment centers CTC’s offer treatment according to the 
Tanzanian Ministry of Health treatment guidelines for the provision of ART. According to these 
guidelines, patients receive a fixed-dose combination of stavudine, lamivudine and nevirapine 
(D4T/3TC/NVP) as first-line ART. Zidovudine (AZT) and efavirenz (EVF) are used in place of 
D4T and NVP respectively, depending upon toxicities and concurrent medications. Each patient 
is typically seen on a monthly basis and their prescriptions refilled. At the time of this study, 
routine viral load monitoring was not available in these CTC’s; therefore, patients were switched 
to second-line ART based on clinical and immunological criteria according to the WHO 
guidelines70 of a decline in CD4+ cell count to the pre-treatment value or below, ≥ 50% decline 
from the peak value CD4+ cell count value while on treatment or persistent low CD4+ cell count 
< 100 c/mm3. The drugs used for second-line ART included tenofovir, abacavir and 
lopinavi/ritonavir; atazanavir/ritonavir (ATZ/r) was substituted for LPV/r as needed. The second-
line nucleoside reverse transcriptase inhibitor (NRTI) choice for adolescents and adults 
depended on the first-line ART. For patients on AZT or D4T in first-line ART, the default second-
line option was TDF combined with 3TC or FTC and LPV/r. For those who had received TDF in 
first-line, the second-line option was an AZT-based regimen. For those who were on TDF during 
first-line because of intolerance to AZT or D4T, an alternative second-line option was abacavir 
(ABC) combined with 3TC or FTC and LPV/r. 
Data collection 
As part of routine HIV clinical care, all patient data including demographics, medication 
use, opportunistic infections, adherence indicators (adherent = fewer than 2 missed days per 
month/non-adherent = 2 or more missed days per month), and laboratory values were collected 
on standardized forms, and entered into a database designed and funded by the Tanzanian 
National AIDS Control Program (NACP) in collaboration with Elizabeth Glaser Pediatric AIDS 
Foundation (EGPAF). This database was searched for clinical data, and when information was 
missing, it was abstracted from their respective medical files. Treatment monitoring included 
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clinical and immunological criteria; CD4+ cell counts were checked at 4-6 month intervals using 
flow cytometry.  
Definition of variables 
The primary end point was the time from immunological failure to the first occurrence of 
opportunistic infections [tuberculosis (TB), pneumonia, Kaposi’s sarcoma (KS), cryptococcal 
meningitis (CM) and herpes zoster (HZ)]. Time of immunological failure began at the visit when 
the failure diagnosis was made. All TB, KS, CM and some pneumonia infections were confirmed 
by the laboratory, histopathology or x-ray, while herpes zoster infections were diagnosed 
clinically. We defined loss to follow-up as the absence of a documented clinic visit six months 
from date of the previous clinic visit.  
The exposure of interest was time until switching to second-line ART. We defined 
switching to second-line as initiation of a boosted PI-based regimen; otherwise, the patient was 
considered not switched. Furthermore, among those switched to second-line, we defined 
immediate and delayed switching as switching occurring at < 3 months versus ≥ 3 months after 
the diagnosis of immunological failure was made, respectively. A cut-off of 3 months was 
chosen because following a failure diagnosis; patients receive 1-2 months of intensive 
adherence counselling prior to making the switch. 
Institutional review board (IRB) approval was obtained from the University of North 
Carolina and KCMC. 
Statistical analyses 
Statistical analyses were conducted using Statistical Analysis Software (SAS) version 
9.3, SAS Institute Inc., Cary, NC, USA. The distribution of continuous variables was explored to 
guide categorization. Frequencies and distributions of sociodemographic and clinical 
characteristics were computed. 
Since switching to second-line ART is influenced by CD4+ cell counts, confounding by 
indication is a potential problem such that patients with low CD4+ cell are more likely to be 
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switched to second-line than those without low CD4+ cell.  We assessed the effect of switching 
to second-line ART on the risk of opportunistic infections using Cox proportional hazards 
marginal structural models (MSM) which address confounding by indication. CD4+ cell count 
was considered as a time-varying confounder. To ensure switching to second-line ART 
happened after a time-varying confounder, CD4+ cell count values at failure diagnosis were 
assigned to the preceding month.  
 Other covariates included age, gender, adherence to first-line ART, adherence to 
second-line ART, treatment sites and duration spent on first-line ART. Patients began 
accumulating person time from the moment failure diagnosis was made, and were followed until 
first occurrence of an opportunistic infection, death, lost to follow-up or end of the study; 
whichever came first. All patients who died, were lost to follow-up, and did not experience 
opportunistic infections were censored in the primary analysis.  
Marginal structural model analyses use inverse probability of exposure weights to control 
confounding by time-varying covariates that are also on the causal pathway from exposure to 
outcome. In this case, the persons were assigned weights inversely proportional to their 
probability of having the exposure, given their exposure and covariate histories. We used 
logistic regression models to compute the weights, and all weights were stabilized. Following 
computation of the stabilized weights, we used Cox proportional hazards marginal structural 
models to estimate the associations. All associations were presented as adjusted hazard ratios 
(AHR) with 95% confidence intervals (CI). Estimates whose confidence intervals excluded 1 
were regarded as statistically significant. 
Kaplan-Meier curves were used to assess the survival distributions among those who 
were switched and those who were not switched to second-line ART. We used log-rank tests to 
compare the hazard functions for those switched against those not switched to second-line 
ART. Poisson regression models were used to compute the incidence rate of opportunistic 
infections. Two sensitivity analyses were performed, first by defining time from failure diagnosis 
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to death or first occurrence of opportunistic infections as the outcome and secondly, by using 
propensity scores weighting to assess the effect of switching to second-line ART on the risk of 
opportunistic infections. In the second case the main exposure switching to second-line ART 
was considered as time fixed mimicking the design of randomized controlled trial where every 
eligible patient would be assigned either to be switched or not at baseline. A Logistic regression 
model was used to generate scores for which we considered the following variables into the 
model: Age (< 30, 30 – 55, > 55), gender, months patient spent on first-line ART (< 36, 36 – 60, 
> 60), CD4 cell count, (< 100, 100 – 200, > 200),sites (tertiary hospital, regional hospital, district 
hospital), percent adherence to first-line ART (< 90, ≥ 90) and percent adherence to second-line 
ART (< 90, ≥ 90). Furthermore, we assessed effect of switching on the risk of opportunistic 
infection by assuming the patient failed between the visit at which physicians have the most 
current CD4 cell count and the prior visit at which the CD4 cell count was measured. We also 
assessed if the effect of switching varied with the site. 
Results  
From May through August 2013, we identified 637 adolescent and adult patients who 
met WHO immunological failure criteria. Of these, 396 (62.2%) switched to second-line ART 
while 241 (38.3%) did not. Among those switched, 233 (58.8%) switched within the first 3 
months from the time failure diagnosis was made.  
Three hundred and ninety four (61.8%) were female and the median age was 39 years 
(Table 5.1). About half (327; 51.3%) came from the KCMC CTC. Most 476 (74.7%) had 
suboptimal adherence to first-line antiretroviral therapy and 360 (56.5%) spent less than 36 
months on first-line ART. Over 60% (n=396, 62.2%) switched to second-line ART; among those 
switched, 260 (65.7%) had optimal adherence to second-line ART. At the time of switching to 
second-line ART, 174 (43.9%) had CD4+ cell count of less than 100/mm3.  
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About one-fifth (n=115; 18.1%) experienced an opportunistic infection. The most 
common infections were pneumonia (n=46; 7.2%) and tuberculosis (n=35; 5.5%). About 5% 
experienced cryptococcal meningitis, Kaposi’s sarcoma, or herpes zoster (n=34; 5.3%). 
Survival distributions among those switched and those not switched to second-
line ART. 
During the follow-up, 637 patients contributed 1181 person-years with overall median of 
follow up of 1.4 years.  Those who switched had a median follow up of 2.3 (IQR; 1.2 – 3.9) 
years, the corresponding median follow up among those who did not switch was 1.0 (IQR; 0.5 – 
1.4) years. Among those who switched, 45 experienced an opportunistic infection (incidence 
rate=5.4 per 100 person-years [95% CI 4.0-7.5]), as compared to 70 among those who did not 
switch (incidence rate=15.9 per 100 person-years [95% CI 12.7-19.9]) The difference in 
probabilities of not developing opportunistic infections among those switched and those who did 
not switch is apparent from the start of follow-up (Figure 5.1). Kaplan-Meier curves showed a 
steep decline during the first 16 months among patients not switched to second-line. The six 
and twelve month probabilities of not having opportunistic infections among those switched to 
second-line ART were 0.97 and 0.93 respectively, as compared to. 0.87 and 0.64 among those 
who did not switch, log rank test,(p < 0.001).  
Compared to patients who met immunological failure criteria and did not switch to 
second-line ART, those who met and switched were less likely to acquire opportunistic 
infections (AHR 0.4, 95% CI 0.2 – 0.6; Table 5.2). 
Compared to patients who switched to second-line ART immediately after their failure 
diagnosis was made, those with delayed switch were more likely to acquire opportunistic 
infections (AHR 1.7, 95% CI 0.6 – 4.4; Table 5.3).  
When the primary end point was defined as death or the occurrence first opportunistic 
infections, compared to patients who met immunological failure criteria and did not switch to 
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second-line ART, those who met and switched were less likely to die or acquire opportunistic 
infections (AHR 0.4, 95% CI 0.2 – 0.6; Table 5.4). 
The logistic regression model used to estimate the propensity score yielded a c-statistic 
of 0.8. The mean propensity to receive second-line ART was 0.7 (standard deviation, 0.2) 
compared with 0.4 (standard deviation 0.2) for those who did not receive second-line ART. The 
distribution of the propensity score for those switched to second-line ART was somewhat higher 
than those who did not switch to second-line, however, about 97.7% of the propensity scores 
overlapped between the two groups. Using propensity scores analyses, compared to patients 
who met immunological failure criteria and did not switch to second-line ART, those who met 
and switched were less likely to acquire opportunistic infections (AHR 0.2, 95% CI 0.1 – 0.2). 
Using the visit at which physicians have the most current CD4 cell count and the prior 
visit at which the CD4 cell count was measured as the time of failure diagnosis, the effect of 
switching to second-line remains to be protective against opportunistic infection. The effect of 
switching to second-line ART did not significantly differ across the sites. 
Discussion 
The study attempted to assess the association between switching to second-line ART 
and the risk of opportunistic infections among HIV-infected patients meeting immunologic failure 
criteria from five CTCs in northern Tanzania. We demonstrated that switching to second-line 
ART reduced the incidence of opportunistic infections among patients meeting immunological 
failure criteria by an estimated 60%. Furthermore, time of switching impacted the risk of 
opportunistic infections with longer delays associated with a 70% increase in risk relative to 
immediate switching.  
In the absence of routine viral load testing for determining treatment failure, delayed 
switching is common in many low- and middle-income countries.17,19,69 In this study, only 62% of 
those meeting immunological failure criteria switched at all and the median time to switch from 
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the time of immunological failure diagnosis was 5.1 months. Limited availability of the second-
line medications, low sensitivity of the WHO immunological failure criteria in predicting 
virological failure and low confidence of health care provider’s in making switches may have 
contributed to the delays in switching. In addition to these factors delays in switching in this 
cohort could as also be explained by the low levels of adherence. About 75% of the patients had 
adherence levels below 90% prior to switch. Those with low levels of adherence may have been 
less likely to be switched. Similar delays in switching were documented in Haiti in which the 
median time to switching to second-line ART was 7 months and patients with adherence below 
90% were less likely to be switched.63 Substantial proportions of patients who met 
immunological failure criteria in a study from Mali 18 did not switch to second-line ART, and the 
median duration of follow-up from failure diagnosis was 5 months. These observations suggest 
that delays in switching to second-line ART are a serious management concern across low- and 
middle-income countries. 
Among patients meeting immunological failure criteria, switching to second-line ART is 
associated with a 60% reduction in the risk of opportunistic infections compared to those who 
remained on a failed first-line regimen. The association between immunological failure and the 
incidence of herpes zoster has been reported previously,94 in which the incidence of herpes 
zoster was 6.2 episodes per 100 person years. We observed a slightly lower incidence rate of 
2.1 episodes per 100 person years. The high incidence of opportunistic infections is likely 
attributable to unrecognized treatment failure and relatively severe immunosuppression. Among 
those who switched, nearly half of the patients in our study had CD4+ cell count less than 100 
c/mm3 at the time of switch. Severe immunosuppression defined by CD4+ cell less than 100 
c/mm3 is a clear risk factor for opportunistic infections such as TB and pneumonia.95,96  
Our sensitivity analyses results were robust with the results from the main analysis. 
Using propensity scores, switching to second-line ART is associated with an 80% reduction in 
the risk of opportunistic infections compared to those who remained on a failed first-line 
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regimen. Combining deaths and opportunistic infections as the end point, the effect of switching 
to second-line persisted; the risk of death or opportunistic infections was less among those 
switched compared to those continued on the failed first-line regimen. Among those who died, 
31% had opportunistic infections before death. Others have shown previously that delayed 
switching is associated with an increased risk of mortality.11,63 Although the causes of death 
were not ascertained in these studies, it is likely patients had life-threatening opportunistic 
infections prior to their deaths.  
Many of the opportunistic infections in this study were clinically diagnosed. Misdiagnosis 
might have overestimated the incidence of opportunistic infections. While it is possible to 
misdiagnose pneumonia infections clinically, the dermatological manifestations of herpes zoster 
are obvious and unlikely to be misdiagnosed in HIV-infected patients. Moreover, clinical 
diagnosis of herpes zoster is common in many studies.94,97,98 Although TB infections were 
confirmed by sputum examination, the presence of smear negative does not rule out TB 
especially so in HIV infected patients. The timing of sputum collection and processing also have 
impact in the diagnosis of TB. Variations in timing and processing from different laboratories 
might have underestimated the incidence of TB infections. 
The timing of diagnosis of opportunistic infections could be measured with some errors 
in this study. Due to the factors related to patients, access to care and health care systems in 
LMIC, diagnoses of TB and KS and other AIDS defining cancers are likely to be made late.99,100 
All patients in this study were screened for TB at ART initiation, and were periodically evaluated 
for TB as they attended their CTC’s. In addition, with monthly clinic visits and periodic evaluation 
errors in the timing of diagnosis of opportunistic infections are likely to be minimal. 
Since CD4+ cell counts were measured at intervals of 4-6 months, the diagnosis of 
treatment failure was made late in most patients, especially those whose CD4+ cells were 
measured at 6 month intervals. In our analyses, the most current CD4+ cell measurements 
were assigned to the previous month to account for possible late treatment failure diagnosis. 
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We did not have HIV- RNA results for the patients and therefore CD4 cell count were 
used to make failure diagnosis. It is likely that some patients considered failed might have not 
failed and those with virological failure might have not been included into the study. Such 
misclassification of the failure diagnosis might have introduced selection bias. Moreover, 
practically, HIV-RNA is known to influence both opportunistic infections and physician’s decision 
in making switches. However, since physicians did not have the knowledge of the HIV-RNA 
results, it is unlikely that their decision were directly influenced by the HIV-RNA. High plasma 
HIV-RNA leads to suppression of the patient’s immunity which is being reflected by the low CD4 
cell count that was controlled for in this study 
Conclusion 
The risk of opportunistic infections and death is reduced among patients switched to second-line 
ART after a diagnosis of immunological failure is made. Furthermore, the risk of opportunistic 
infection is higher when the delay to switch is 3 months or longer from the time of failure. Delay 
in switching could mainly be due uncertainties physicians have due to the relatively poor ability 
of the WHO immunological failure criteria to predict virological failure. If true, efforts should be 
put to invest on the viral load testing equipment in order to improve the timing of failure 
diagnosis and manage patients accordingly. This could be made possible by placing a central 
testing laboratory where patient’s dry blood spots from different care and treatment centers 
could be evaluated. Dry blood spot is known to reduce logistic difficulties and the cost that is 





Table 5.1: Demographic and clinical characteristics of HIV-infected adolescents and adults meeting WHO 
immunological failure criteria  at five infectious disease clinics in Kilimanjaro Region, Moshi, Tanzania, 2004-2013. 
Variable 
Overall                                       
n = 637 
Switched to                               
second-line
(n=396) 
Did not switch to                  
second-line 
(n=241) 
Gender                                           Male 243 (38.2) 146 (36.9) 97 (40.2) 
                                                       Female 394 (61.8) 250 (63.1) 144 (59.8) 
Age (IQR)                                       Median years  39 (32.0 – 46.0) 38 (30.0 – 45.0) 40 (34.0 – 48.0) 
Duration on first-line ART               < 36 months 360 (56.5) 222 (56.1) 138 (57.3) 
                                                       36  – 60 months 187 (29.4) 146 (31.8) 61 (25.3) 
                                                       > 60 months 90 (14.1) 28 (12.1) 32 (17.4) 
First-line adherence                       Optimal 161 (25.3) 98 (24.8) 63 (26.1) 
                                                       Suboptimal 476 (74.7) 298 (75.2) 178 (73.9) 
Second-line adherence*                 Optimal 260 (40.8) 260 (65.7) N/A 
                                                       Suboptimal 136 (21.3) 136 (34.4) N/A 
CD4 cells at time of switch*           < 100 c/mm³ 174 (27.3) 174 (43.9) N/A 
                                                       100 – 200 c/mm³ 166 (26.0) 166 (41.9) N/A 
                                                       > 200 c/mm³ 56 (8.8) 56 (14.1) N/A 
Sites                                               Tertiary hospital 327 (51.3) 244 (61.6) 83 (34.5) 
                                                       Regional Hospital 167 (26.2) 92 (23.2) 75 (31.1) 
                                                       District Hospital 143 (22.5) 60 (15.2) 83 (34.4) 
Infections*                                      Tuberculosis 35 (5.5) 14 (3.5) 21 (8.7) 
                                                       Pneumonias 46 (7.2) 19 (4.8) 37 (15.4) 
                                                       Meningitis 1 (0.2) 0 (0.0) 1 (0.4) 
                                                       Kaposis sacorma 8 (1.3) 3 (0.8) 5 (2.1) 
                                                       Herpes zoster 25 (3.9) 9 (2.3) 16 (6.6) 




Table 5.2: Risk factors of opportunistic infections among HIV-infected adolescents and adults switched and those 
not switched into second-line antiretroviral therapy at five infectious disease clinics in Kilimanjaro Region, Tanzania, 2004-
2013* 








Switched No 77 483.3 15.9 1 
 
Yes 38 697.3 5.4 0.4 (0.2 – 0.6) 
Gender Male 43 489.1 8.8 1 
 
Female 72 691.5 10.4 1.2 (0.8 – 1.7) 
Age < 30 years 27 270.4 10.0 1 
 
30 – 55 years 80 827.0 9.7 0.9 (0.5 – 1.5) 
 
>55 years 8 83.2 9.6 0.6 (0.3 – 1.5) 
Duration on first-line ART < 36 months 76 647.4 11.7 1 
 
36 – 60 months 29 371.2 7.8 0.5 (0.3 – 0.8) 
 
>60 months 10 161.9 6.2 0.3 (0.1 – 0.6) 
First-line adherence Optimal 20 357.2 5.6 1 
 
Suboptimal 95 823.4 11.5 1.5 (0.9 – 2.4) 
Second-line adherence Optimal 43 686.3 6.2 1 
 
Suboptimal 72 494.3 14.6 1.3 (0.8 – 1.9) 
Sites Tertiary hospital 54 738.3 7.3 1 
 
Regional Hospital 30 251.8 11.9 1.1 (0.7 – 1.8) 
 
District Hospital 31 190.4 16.3 1.3 (0.8 – 2.1) 
 
* Hazards ratios are based on analysis of Cox proportional marginal structural models on 636 patients                                                                                                                             






Table 5.3: Risk factors of opportunistic infections among HIV-infected adolescents and adults switched into second-
line antiretroviral therapy at five infectious disease clinics in Kilimanjaro Region, Tanzania 2004 – 2013.* 
Variable 
Number                                  
of  infections 




Adjusted HR           
(95% CI)  
Delayed                              No             11 413.4 2.7 1 
                                           Yes 27 505.4 5.3 1.7 (0.6 – 4.4) 
Gender                               Male 15 368.9 4.0 1 
                                           Female 23 550.0 4.2 1.4 (0.6 – 3.2) 
Age                                     < 30 years 12 232.7 5.2 1 
                                           30 – 55 years 22 632.8 3.5 0.3 (0.1 – 0.9) 
                                           > 55 years 4 53.3 7.5 1.8 (0.1 – 4.2) 
Duration on first-line ART  < 36 months 22 536.5 4.1 1 
                                           36  – 60 months 11 290.3 3.8 1.0 (0.3 – 3.6) 
                                           > 60 months 5 92.1 5.4 0.4 (0.1 – 1.3) 
First-line adherence           Optimal 5 285.3 1.7 1 
                                           Suboptimal 33 633.5 5.2 4.1 (1.4 – 12.6) 
Second-line adherence      Optimal 26 675.6 3.8 1 
                                           Suboptimal 12 243.3 4.9 1.7 (0.6 – 5.2) 
Sites                                   Tertiary hospital 22 648.7 3.4 1 
                                           Regional Hospital 11 172.6 6.4 2.1 (0.7 – 6.1) 
                                           District Hospital 5 97.6 5.1 1.0 (0.3 – 3.7) 
* Hazards ratios are based on analysis of Cox proportional marginal structural models on 396 patients                        







Table 5.4: Analyses on the effect of delayed switching on the risk of opportunistic infections/deaths among HIV-
infected adolescents and adults switched to second-line antiretroviral therapy at five infectious disease clinics in 
Kilimanjaro Region, Tanzania 2004 – 2013.* 
Variable 
Number                                  
of  infections 
Person                
years Rate/100 py 
Adjusted HR           (95% 
CI)  
Switched                                      
No             92 487.7 18.9 1 
                                                    
Yes 47 700.3 6.7 0.4 (0.2 – 0.6) 
 
*Hazard ratio based on analysis of Cox proportional marginal structural models on 637 patients                                                                   





Figure 5.1: Kaplan-Meier curves for 637 HIV
 
 





CHAPTER 6: DISCUSSION 
The study attempted to explore adherence to antiretroviral therapy and the frequency of 
opportunistic infections among HIV-infected adolescent and adult patients meeting WHO 
immunological failure criteria in Northern Tanzania. The aims of this study were (1) To 
determine the association of adherence to first-line antiretroviral therapy with adherence to 
second-line antiretroviral therapy (2a) To determine the effect of delayed switching to second- 
line antiretroviral therapy on the risk of opportunistic infections among patients meeting WHO 
immunological failure criteria and (2b) To determine the effect of switching to second-line 
antiretroviral therapy on the risk of opportunistic infections among patients meeting WHO 
immunological failure criteria. To address the first aim we conducted a cross-sectional study in 
which participants were interviewed about their adherence practices before and after switching 
to second-line antiretroviral therapy. We conducted retrospective review of patient’s medical 
charts to address the second aim. 
Summary of the findings 
Aim 1: Association of adherence to first-line ART with adherence to second-line 
ART 
Most patients who had suboptimal adherence prior to switch continued to have 
suboptimal adherence even after switch. Patients who had suboptimal adherence to
first-line ART were 2.4 times as likely to have suboptimal adherence to second-line as those 







Adherence to antiretroviral therapy is still a major concern. Most patients with poor 
adherence continued to be non-adherent even after receiving adherence counselling. The 
existing effect size of the association between adherence to first-line ART and adherence to 
second-line ART should be interpreted with care given the nature of the study design, biases 
and the method of adherence assessment. For example, adherence to first-line therapy was 
assessed when patients have already been switched to second-line therapy; given the long time 
the person has been on first-line, recall bias is likely.   
Public health significance 
This study is one the first to directly explore the association of adherence to first-line 
ART and that of adherence to second-line. Antiretroviral therapy reduced morbidity and mortality 
associated with HIV and its associated opportunistic infections and near perfect adherence is 
the key of the success. Given the limited availability of treatment options of the patients failing 
first-line and that second-line ART is the final salvage regimen in most resource poor settings, 
our findings underscore the need to re-address medication non-adherence in patients prior to 
switching to second-line therapy to improve their outcomes  
Future directions 
In this study, we identified adherence to first-line ART as an important predictor of 
adherence to second-line ART. Practices of improving adherence in these care and treatment 
centers involves patient provider counselling every time patients come for prescription refill. 
Although such practice is useful, it may not be sufficiently effective. In addition to routine 
individual counselling, we suggest involvement of peer supports and supervisory home based 
care that proved to improve adherence as well as retention of patients to care.50 Although 
home-based care is challenging due to shortage of staff and long distance to patient’s premises, 
its implementation may not be demanding in these moments when treatment and care programs 
have been decentralized. Since this was the first study to directly assess the association 
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between adherence to first-line ART and adherence to second-line ART, we suggest other 
investigators conduct studies to further explore this relationship. 
Summary of the findings 
Aim 2: Switching and risk of opportunistic infections 
Among patients meeting WHO immunological failure criteria, switching to second-line 
reduced the risk of opportunistic infection by 60%. Among those switched to second-line, 
switching at 3 months or more after failure diagnosis is made is associated with increased risk 
of opportunistic infections. 
Interpretation 
Our study highlights that delayed switching to second line ART is common. About 74% 
of the patients who met WHO immunological failure criteria in our study did not receive second-
line therapy in a timely manner, meaning they were either not switched or switching happen at 3 
month or more after failure diagnosis was made. Timely switching reduced risk of opportunistic 
infections and deaths. 
Public health significance 
Low rates of switching to second-line appears common, despite increasing number of 
patients receiving first-line.18,68,69 Furthermore, patients meeting clinical and immunological 
failure criteria also experience delayed switching to second line.63,92 We hypothesized that 
delays in switching could pose an increased risk of opportunistic infections among patients with 
unrecognized treatment failure. Our observations supported our hypothesis: the risk of 
opportunistic infections was higher among patients who met WHO immunological failure criteria 
and did not switch to second line ART. Furthermore, the risk of death was also higher among 
those who did not switch. The research carries important public health significance, in order to 






In this study, we identified delayed switching to second-line ART increases the risk of 
opportunistic infections or deaths. We suggest more investment in viral load testing equipment 
is needed to improve the timing of failure diagnosis and manage patients accordingly. Viral load 
testing could be made possible using a central testing laboratory and shipped dry blood spots. 
Dry blood spot reduce logistic difficulties and the cost that is associated with the use of plasma. 
101
 In addition, physician education on the importance of adhering to treatment guidelines is 
critical in order to reduce variation in switching times. 
Overall our study carries important implementation science messages that emphasize 
the need to incorporate adherence interventions to patients with mal-adherence problems. 
Involvement of peer support and home based care services are affordable and sustainable over 
long time at these times where ART services have been decentralized. Furthermore, the study 
increased physicians and health care provider’s awareness on the timing of switching patients 
to second-line ART. It is hoped that improving the diagnosis of treatment failure would result in 




APPENDIX 1: INFORMED CONSENT 
Consent to participate in a Research Study Entitled “Causal effect of switching to second-line 
antiretroviral therapy and the risk of opportunistic infections in Northern Tanzania”. 
IRB study # 13-1862 
Consent Form Version Date: May 20, 2013. 
Principal Investigator: Habib Ramadhani Omari 
Funding source: Duke AIDS International Training Research Program (AITRP) 
INTRODUCTION 
You are being asked to take part in this research study because you are infected with HIV, the 
virus that causes AIDS, and you have been switched to second-line antiretroviral therapy. This 
study is sponsored by the Duke Aids International Training Research Program (AITRP) which is 
funded through the National Institute of Health (NIH) in the United States. This study is under 
the direction of Dr Habib Ramadhani and Dr Venance Maro at Kilimanjaro Christian Medical 
Centre (KCMC) and Dr. John Bartlett from Duke University Health Systems.  Research studies 
are voluntary and include only people who choose to take part. Please read this consent form 
carefully and take your time making your decision. As your study staff member discusses this 
consent form with you, please ask him/her to explain any words or information that you do not 
clearly understand. The nature of the study, risks, inconveniences, discomforts, and other 
important information about the study are listed below. You are free to ask questions about this 
study at any time. If you agree to take part in this study, you will be asked to sign and date this 
consent form. You will get a copy to keep. 
WHY IS THIS STUDY BEING DONE? 
The purpose of this study is to evaluate the association of adherence to first-line antiretroviral 





WHAT DO I HAVE TO DO IF I AM IN THIS STUDY? 
Screening 
If you think you would like to join in this study, you will be asked to sign a consent form. You will 
be asked questions and examined to check your overall health. You will be asked questions 
about your adherence experience before and after you have been switched to second-line 
antiretroviral therapy. 
If you do not enroll into the study 
After signing the consent, if you decide not to take part in this study or if you don’t meet eligibility 
requirements, we will still use some of your information. As part of the screening visit, data are 
being collected from you that might be useful for researchers. You are being asked to allow the 
researchers to keep some of the demographic (for example age, gender, race), clinical (for 
example disease condition, diagnosis)   information that was collected during the screening visit 
in a database. You will be given a unique code number that will be used on all your information 
so that your identity will not be known. 
Entry 
If you have met all eligibility criteria to enter the study, you will be interviewed right away if you 
decide to take part in this study. You will be asked questions about your health and questions 
pertaining to medication adherence. 
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY? 
About 400 people will take part in this study. All study participants will be recruited from KCMC, 
Mawenzi, Kibosho, Kilema and Machame infectious disease clinics. 
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to take part in this study you will only be available at the time of being interviewed. 





WHAT ARE THE RISKS OF THE STUDY? 
Risk of loss of confidentiality 
It is possible that participating in this study will make it difficult for you to keep your HIV status 
secret from people close to you. This may lead to unwelcome discussions about or reactions to 
your HIV status. Please talk with the study staff if you have any concerns in this regard. We will 
do everything we can to protect your confidentiality but this cannot be guaranteed. 
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY? 
If you decide to take part in this study, there may or may not be direct medical benefit to you. 
Your health care provider will have results of adherence practices. He/she may plan to discuss 
with you how best you can be assisted to improve your adherence. We also hope the 
information learned from this study will benefit other people with HIV in the future. 
WHAT OTHER CHOICES DO I HAVE BESIDES THIS STUDY? 
Instead of being in this study you have the choice of treatment with the same or other anti HIV 
drugs available to you outside of the study. 
WILL MY INFORMATION BE KEPT CONFIDENTIAL? 
Study records that identify you will be kept confidential as required by law. Federal Privacy 
Regulations provide safeguards for privacy, security and authorized access. Except when 
required by law, you will not be identified in study records disclosed outside of Duke University 
or KCMC. For records disclosed outside Duke University or KCMC, you will be assigned a 
unique code number. The key to the code will be kept in a locked filed in the research staff 
offices. In addition, your records may be reviewed in order to meet Tanzanian and U.S. 
regulations. Reviewers include U.S. Office for Human Research Protections (OHRP), the 
National Ministry of Health in Tanzania, KCMC Ethic Committee, the Duke University Health 
Systems Institutional Review Board (IRB), the U.S. NIH, study staff, and study monitors. If any 
of these groups review your research record, they may also need to review your entire medical 
record. The study results will be retained in your research record forever. Any research 
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information in your medical record will also be kept indefinitely. If this information is disclosed to 
outside reviewers for audit purposes, it may be further disclosed by them and may not be 
covered by the federal privacy regulations. This information may be further disclosed by the 
sponsor of this study, the U.S. NIH. If disclosed by the sponsor, the information is no longer 
covered by the federal privacy regulations. While the information and data resulting from this 
study may be presented at scientific meetings or published in a scientific journal, your identity 
will not be revealed. 
WHAT ARE THE COSTS TO ME? 
There are no additional costs related to participating in this study. 
WILL I RECEIVE ANY PAYMENTS? 
There will be no financial compensation for participating in this study. 
WHAT ABOUT RESEARCH RELATED INJURIES? 
Immediate necessary care and support is available if an individual is injured because of 
participation in this research project, however, there is no provision for free medical care or for 
monetary compensation for such an injury. For questions about the study or research-related 
injury, contact Dr. Venance Maro at 0754 581444. 
WHAT ARE MY RIGHTS AS STUDY PARTICIPANT? 
Taking part in this study is completely voluntary. You may decide not to take part in this study or 
leave this study at any time. You will be treated the same no matter what you decide. Your 
decision to not participate or to withdraw from the study will not involve any penalty or loss of 
benefits to which you are entitled, and will not affect your access to health care at KCMC, 
Mawenzi, Kibosho, Kilema or Machame. If you do decide to withdraw, we ask that you contact 
Dr. Venance Maro in writing and let him know that you are withdrawing from the study. His 
mailing address is KCMC-Duke Collaboration, Box 3010, Sokoine Road, Moshi. We will tell you 
about new information from this or other studies that may affect your health, welfare or 
willingness to stay in this study. If you want the results of the study, let the study staffs know. 
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WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study or a research-related injury, or if you have complaints, concerns 
or suggestions about the research, contact Dr. Venance Maro at 0754 581444. For questions 
about your rights as a research participant, or to discuss problems, concerns or suggestions 
related to the research, or to obtain information or offer input about the research, contact the 
Kilimanjaro Christian Medical Centre (KCMC) Ethics Committee at telephone number (255) 27 
27-53909 or the Duke University Health Systems Institutional Review Board at +1-919-668-
5111. 
STATEMENT OF CONSENT 
"The purpose of this study, procedures to be followed, risks and benefits have been explained 
to me. I have been allowed to ask the questions I have, and my questions have been answered 
to my satisfaction. I have been told whom to contact if I have additional questions. I have read 
this consent form and agree to be in this study with the understanding that I may withdraw at 
any time. I have been told that I will be given a signed and dated copy of this consent form to 
keep." 
_____________________________________________________________________ 
Participant’s Name (Print)    Participant’s Signature   Date  
 
"As the representative of the subject, I am acting on behalf of the subject and am aware of no 
factor that would be considered to create a conflict of interest (such as a potential independent 
personal benefit) for me in consenting to the subject's participation in this study." 
_____________________________________________________________________ 
Participant’s legally Authorized Representative’s Signature    Date  
 
______________________________________ 
Representative (print) (As appropriate) 
 
_____________________________________________________________________ 









APPENDIX 2: ADHERENCE QUESTIONNAIRE 
ASSOCIATION OF FIRST-LINE ANTIRETROVIRAL THERAPY ADHERENCE WITH 
ADHERENCE TO SECOND-LINE ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED 
PATIENTS IN TANZANIA. 
 
Study subject ID number: _________Date (dd-mm-yyyy):    __ __ - __ __ - __ __ __ __  
 
Study subject initials:    Abstractor’s (full name): _____________________ 
 
INSTRUCTIIONS 
Check that the patient has been taking ARV’s for 6 months or more before starting 
Use the patient medical records when necessary 
Ask the patient all the questions in this questinnaire 
Following the instructions in italics in the right hand column 
When you are filling boxes, right- justify your answer 
 
1.1 What is your sex?  
Choose only one. 




1.2 What is your date of birth? 
 If only year is known, please code as 01-
07-yyyy 
 (dd-mm-yyyy) 
 ___ ___ - ___ ___ - ___ ___ ___ ___ 
 
1.3 What district do you live in?  
Choose only one 














If answer is other, specify 
here:___________________ 
1.4 What region do you live in?  
Choose only one 















If answer is other, specify 
here:____________________ 
1.5 Do you know CD4 cell count? Yes………………………………….1 
 
No……………………………………2 
1.6 Is high CD4 cell count good or bad? Good………………………………...1 
 
Bad…………………………………..2 
1.7 When does the CD4 cell count rises? When you take your medication 
constantly…………………………..1 
 
When you don’t take your medication 
constantly…………………………..2 







1.9 How do you take your medications 
now 
Once a day………………………1 
 
Twice a day..…………………….2 
 
Thrice a day……………………..3 
1.10 How many doses of medication did 
you skip today? 
 
 
1.11 How many doses of medication did 
you skip yesterday? 
 
1.12 How many doses of medication did 
you skip a two days ago 
 
 
1.13 Ever since you switched to second-
line, can you estimate the amount of medication 
you have been taking e.g 
0% = you did not take any of the 
prescribed drugs 
25%= you took only ¼ of the prescribed 
drugs 




75% = you took only ¾ of the prescribed 
drugs 





Before you switched to second
you 
estimate the amount of medication you 
have been taking e.g 
0% = you did not take any of the 
prescribed drugs 
25%= you took only ¼ of the prescribed 
drugs 
50%= you took only 1/5 of the prescribed 
drugs 
75% = you took only ¾ of the 
drugs 
















APPENDIX 3: QUESTIONNAIRE 
CAUSAL EFFECT SWITCHING INTO SECOND LINE ART AND THE RISK OF 
OPPORTUNISTIC INFECTIONS IN NORTHERN TANZANIA 
 STUDY QUESTIONNAIRE 
 
Study subject ID number: ________________Date (dd-mm-yyyy):    __ __ - __ __ - __ __ __ __  
 





Check that the patient has been taking ARV’s for 6 months or more before starting 
Use the patient medical records  
Following the instructions in italics in the right hand column 




1.1 What is your sex?  
Choose only one. 




1.2 What is your date of birth? 
 If only year is known, please code as 01-
07-yyyy 
 (dd-mm-yyyy) 
 ___ ___ - ___ ___ - ___ ___ ___ _ 
 
1.3 What district do you live in?  
Choose only one 
Circle the answer 
Moshi rural.................................1 
 











If answer is other, specify 
here:___________________ 
1.4 What region do you live in?  
Choose only one 
















If answer is other, specify 
here:____________________ 
1.5 Visit number 
 
 
1.6 Visit date dd-mm-yyyy)  
 
___ ___ - ___ ___ - ___ ___ ___ __ 
 
1.7 Patient weight  
 
 
1.8 Patient height  
 









1.10 What is your marital status? 
Choose only one 
Circle the answer 
Married (monogamous)…........1 
 























 ___ ___ - ___ ___ - ___ ___ ___ ___ 
 
2.2 ART Regimen 
Choose only one 
Circle the answer 
D4T + 3TC + NVP….....................1 
 
D4T + 3TC + EVF.........................2 
 
AZT + 3TC + NVP.........................3 
 
AZT + 3TC + EVF.........................4 
 
TDF + 3TC + LPVr/ATVr...............5 
 
TDF + FTC + LPVr/ATVr...............6 
 
ABC + DDI + LPVr/ATVr...............7 
 
2.3 Type of ART? 
Choose only one 





2.4 Is the patient switched? 
Choose only one 





2.5 Date switched dd-mm-yyyy) 
 
 ___ ___ - ___ ___ - ___ ___ ___ ___ 
 







































4.1 CD4 cell count (CD4) 
 
 
4.2 Is CD4 cell count less or equal to 
baseline? 








4.3 Is CD4 cell count persistently less 
than 100 for the past 6 months? 







3.0 Do you have opportunistic infections? 
 
Choose only one 














3.1 Date of diagnosis dd-mm-yyyy)  
 
___ ___ - ___ ___ - ___ ___ ___ ___ 
 






4.4 Has CD4 cell dropped>50% of the 
maximum value? 













4.6 Date of failure (datefail) dd-mm-yyyy) 
 
 ___ ___ - ___ ___ - ___ ___ ___ ___ 
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